Cargando…

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have had a profound impact on the treatment of many tumors; however, their effectiveness against triple-negative breast cancers (TNBCs) has been limited. One factor limiting responsiveness of TNBCs to ICIs is a lack of functional tumor-infiltrating lym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamashita, Nami, Long, Mark, Fushimi, Atsushi, Yamamoto, Masaaki, Hata, Tsuyoshi, Hagiwara, Masayuki, Bhattacharya, Atrayee, Hu, Qiang, Wong, Kwok-Kin, Liu, Song, Kufe, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839859/ https://www.ncbi.nlm.nih.gov/pubmed/33495298 http://dx.doi.org/10.1136/jitc-2020-002115

Ejemplares similares

Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer
por: Yamashita, Nami, et al.
Publicado: (2022)

MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells
por: Morimoto, Yoshihiro, et al.
Publicado: (2023)

MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas
por: Luan, Zhou, et al.
Publicado: (2021)

Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment
por: Morimoto, Yoshihiro, et al.
Publicado: (2022)

MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells
por: Hagiwara, Masayuki, et al.
Publicado: (2021)

MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer
por: Hagiwara, Masayuki, et al.
Publicado: (2022)

Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer
por: Fushimi, Atsushi, et al.
Publicado: (2022)

MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells
por: Bhattacharya, Atrayee, et al.
Publicado: (2022)

MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells
por: Yamashita, Nami, et al.
Publicado: (2023)

MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
por: Yamashita, Nami, et al.
Publicado: (2023)

Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression
por: Yamashita, Nami, et al.
Publicado: (2022)

MUC1-C intersects chronic inflammation with epigenetic reprogramming by regulating the set1a compass complex in cancer progression
por: Bhattacharya, Atrayee, et al.
Publicado: (2023)

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2020)

Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2020)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx
por: Gandhi, Shipra, et al.
Publicado: (2023)

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
por: Hiraki, Masayuki, et al.
Publicado: (2018)

Correction: MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
Publicado: (2021)

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression
por: Bruni, Sofia, et al.
Publicado: (2023)

SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response
por: Tanagala, Kranthi Kiran Kishore, et al.
Publicado: (2022)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Peritumoral administration of IFNβ upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model
por: Mao, Jiaji, et al.
Publicado: (2020)

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes
por: Murtas, D, et al.
Publicado: (2013)

Systemic maternal inflammation promotes ASD via IL-6 and IFN-γ
por: Majerczyk, Daniel, et al.
Publicado: (2022)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022)

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
por: Conway, Jordan W, et al.
Publicado: (2022)

Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma
por: de Vries-Brilland, Manon, et al.
Publicado: (2023)

GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
por: Caforio, Matteo, et al.
Publicado: (2021)

MUC1-C activates EZH2 expression and function in human cancer cells
por: Rajabi, Hasan, et al.
Publicado: (2017)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia
por: Choi, Jeong Uk, et al.
Publicado: (2021)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
por: Zhang, Huihui, et al.
Publicado: (2022)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer
por: Yin, Chi, et al.
Publicado: (2023)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer
por: Park, Hyung Soon, et al.
Publicado: (2021)

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
por: Meneveau, Max O, et al.
Publicado: (2022)

Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma
por: Chakiryan, Nicholas H, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7oni518qh1654djse1hm4mmigf